Zura Bio Ltd
NASDAQ:ZURA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zura Bio Ltd
NASDAQ:ZURA
|
US |
|
Sadbhav Engineering Ltd
NSE:SADBHAV
|
IN |
|
T
|
Taier Heavy Industry Co Ltd
SZSE:002347
|
CN |
Zura Bio Ltd
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California. The company went IPO on 2021-07-16. The firm is advancing immunology assets into phase II development programs, including ZB-168 and torudokimab. ZB-168 is an anti-interleukin-7 receptor subunit alpha (IL7Rα) inhibitor that has the potential to impact diseases driven by interleukin-7 (IL7) and thymic stromal lymphopoietin (TSLP) biological pathways. The firm focuses on developing a portfolio of therapeutic indications for ZB-168 that build on existing Phase Ib data in type 1 diabetes demonstrating a safety profile and biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL33), and is in the phase II clinical development stage.
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California. The company went IPO on 2021-07-16. The firm is advancing immunology assets into phase II development programs, including ZB-168 and torudokimab. ZB-168 is an anti-interleukin-7 receptor subunit alpha (IL7Rα) inhibitor that has the potential to impact diseases driven by interleukin-7 (IL7) and thymic stromal lymphopoietin (TSLP) biological pathways. The firm focuses on developing a portfolio of therapeutic indications for ZB-168 that build on existing Phase Ib data in type 1 diabetes demonstrating a safety profile and biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL33), and is in the phase II clinical development stage.
